Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine-Reference-Cited by-同舟云学术

Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine

Published:2017 Issue:17 Volume:56 Page:2367-2371
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Akiyama Norimichi¹,Karayama Masato¹²,Iwaizumi Moriya³,Kusama Yukiko⁴,Kono Masato¹,Hozumi Hironao¹,Suzuki Yuzo¹,Furuhashi Kazuki¹,Enomoto Noriyuki¹,Fujisawa Tomoyuki¹,Nakamura Yutaro¹,Inui Naoki⁵,Suda Takafumi¹

Affiliation:

1. Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Japan

2. Department of Clinical Oncology, Hamamatsu University School of Medicine, Japan

3. First Department of Medicine, Hamamatsu University School of Medicine, Japan

4. Department of Pathology, Hamamatsu University School of Medicine, Japan

5. Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/56/17/56_8312-16/_pdf

Reference21 articles.

1. 1. Mariotto AB, Rowland JH, Ries LAG, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 16: 566-571, 2007.

2. 2. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12: 20-37, 2007.

3. 3. A review of the definition for multiple primary cancers in the United States. In: Workshop Proceedings from December 4-6, 2002, in Princeton, New Jersey. Howe HL, Ed. Springfield (IL), 2003.

4. 4. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311: 1998-2006, 2014.

5. 5. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives;Cancers;2022-02-23

2. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma;Medical Oncology;2020-11

3. Multiple drugs;Reactions Weekly;2017-10